Fosun Pharma Announces 2024Q3 Financial Results
Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 30, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first three quarters of 2024....
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
SHANGHAI, Oct. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a growth advisory firm. This marks the eighth consecutive year that WuXi...
Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA® (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting
Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC), ZYMFENTRA® is the first and only FDA-approved subcutaneous infliximab Late-breaking post hoc analysis of the LIBERTY studies suggests no meaningful differences in efficacy...
I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population
More than 100 million people in the US have this HLA-A haplotype PALO ALTO, Calif., Oct. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are homozygous...
LILYSILK Continues Partnership with National Breast Cancer Foundation for Breast Cancer Awareness Month
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- LILYSILK, the world's leading silk brand with a mission to inspire people to live better, sustainable lives, proudly continues its collaboration with National Breast Cancer Foundation, Inc.® (NBCF) this Breast Cancer Awareness Month to raise awareness about early detection, education, and support services. Through this partnership, LILYSILK remains committed to philanthropy, donating...
Complete Genomics integrates NVIDIA Parabricks to offer researchers faster, more cost-effective and accurate genomic sequencing analysis
Complete Genomics DNBSEQ data and NVIDIA Parabricks yield deeper insights into genetic variants with deep learning SAN JOSE, Calif., Oct. 29, 2024 /PRNewswire/ -- Complete Genomics today announced an integration of its next-generation sequencing (NGS) DNBSEQ platforms* with NVIDIA Parabricks software for secondary analysis that will help researchers access accurate, faster and more affordable genomic analysis. While NGS has...
DeepQure Presents Clinical Results of Laparoscopic RDN at TCT 2024, Demonstrating Cutting-edge Technology and Innovation
SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DeepQure, a global pioneer in resistant hypertension treatment, has unveiled clinical results of its laparoscopic renal denervation (RDN) medical device "HyperQure". Designed to treat resistant hypertension, HyperQure uses a laparoscopic approach to block the sympathetic nerves surrounding the renal arteries. On October 29, DeepQure announced its participation in TCT 2024...
CAS introduces stereoselective labeling in the CAS SciFinder® retrosynthesis tool – a first-of-its-kind capability in the world of scientific technology solutions
The new capability combines the industry-leading CAS Content Collection™ with cutting-edge technology and enables scientists to innovate with confidence COLUMBUS, Ohio, Oct. 29, 2024 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, now offers precise labeling of stereoselective steps within CAS SciFinder predictive retrosynthesis. Available within...
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a written notice (the "Compliance Notice")...
Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.
CHENGDU, China, Oct. 29, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: BGM) is pleased to announce that effective on October 30, 2024, the Company will change its name to "BGM Group Ltd." In connection with the name change, the trading symbol of the Company's Class A ordinary shares has been changed to "BGM" on...
